Wnt inhibitor XNW7201 in Evopoint obtained the ethical approval to conduct Phase IIa clinical trial

XNW7201 is a porcupine inhibitor against Wnt signaling pathway with independent intellectual property rights owned by Evopoint Biosesciences Co., Ltd. It was approved by Beijing Cancer Hospital, the unit of the team leader, for the Phase IIa clinical trial on October 18, 2021.

Variation of Wnt signaling pathway is common in gastrointestinal tumors (e.g., gastric cancer, colorectal cancer, esophageal cancer, pancreatic cancer, etc.). Inhibition of Porcupine protein can block the abnormally activated Wnt signaling pathway. Moreover, it has been confirmed that the use of Wnt inhibitor is expected to enhance the effect of tumor immunotherapy. In this regard, Evopoint will continue to make every effort to promote the Phase IIa clinical trial of XNW7201 and strive to accelerate product launch for the benefit of numerous sufferers.